Found 18 results
Author Title [ Type(Desc)] Year
Filters: Author is Schmidt, C  [Clear All Filters]
Conference Paper
P. Hayes, Fernandez, N., Omosa-Manyonyi, G., Mpendo, J., Karita, E., Ruzagira, E., Kilembe, W., Mutua, G., Anzala, O., Roman, F., Bourguignon, P., Barin, B., Eldridge, J., Egan, M., Hannaman, D., Schmidt, C., Fast, P., Priddy, F., Cox, J., and Gilmour, J., Assessment of Viral Inhibition Activity in Low Seroprevalent Adenovirus-35 Vectored HIV Vaccines +/- Adjuvanted Protein or Electroporated DNA, in HIV Research for Prevention 2014: AIDS Vaccine, Microbicide and ARV-based Prevention Science (HIVR4P), Cape Town, SA, 2014.
S. Vasan, Schlesinger, S. J., Chen, Z., Hurley, A., Than, S., Adesanya, P., Bunce, C., Boaz, M., Boyle, R., Sayeed, E., Gardiner, D. F., Zaharatos, G. J., Caskey, M., Q, F., Schmidt, C., Huang, Y., Seamons, L., Ho, M., Lombardo, A., Gilmour, J., Keefer, M. C., Fast, P., and Ho, D. D., Cellular and Humoral Immunogenicity of ADMVA, a Clade C/B MVA-Based HIV-1 Candidate Vaccine, in Healthy Volunteers, in AIDS Vaccine 2007 Conference, Seattle, WA, 2007.
O. G Manyonyi, Jaoko, W., Wakasiaka, S., Bwayo, J., Achola, N. J., Schmidt, C., Bhatt, K., Ogutu, H., K’owino, D., Dally, L., Malogo, R., and Fast, P., Challenges Experienced By the Clinical Team During The Conduct of HIV Vaccine Clinical Trials in Kenya, in AIDS Vaccine 2005 International Conference, Montreal, Quebec, Canada, 2005.
H. Ogutu, Wakasiaka, S., Malogo, R., Ndambuki, R., Nyange, J., Omosa, G., Anzala, O., Bwayo, J., Fast, P., Schmidt, C., Verlinde, C., Smith, C., Ndinya-Achola, J., and Jaoko, W., Challenges of Use and Compliance With Effective Contraceptives Among Female Participants in Preventive HIV Vaccine Trials: The Kenyan Experience, in AIDS Vaccine 2007 Conference, Seattle, WA, 2007.
G. Mutua, Mutengu, L., Mpendo, J., Kilembe, W., Omosa, G., Ruzagirwa, E., Karita, E., Page-Shipp, L., Gray, G., Bekker, L. G., Barin, B., Schmidt, C., Laufer, D., and Priddy, F., Major Negative Social Impacts are Rare in Phase 1 HIV Vaccine Trials in Africa, in HIV Research for Prevention 2014: AIDS Vaccine, Microbicide and ARV-based Prevention Science (HIVR4P), Cape Town, SA, 2014.
E. Vardas, Kaleebu, P., Bekker, L., Hoosen, A., Chomba, E., Johnson, P., Heald, A., Anklesaria, P., Dally, L., Boaz, M., Fast, P., and Schmidt, C., A Phase 2 Study to Evaluate the Safety and Immunogenicity of a Recombinant Adeno-Associated Virus HIV Vaccine, in AIDS Vaccine 2007 Conference, Seattle, WA, 2007.
B. Peters, Jaoko, W., Anzala, O., Judges, L., G Manyonyi, O., Sharp, A., Gray, K., Fast, P., Schmidt, C., Gilmour, J., Smith, C., Dally, L., Loughran, K., Farah, B., Tarragona, T., Hayes, P., McMichael, A., Hanke, T., and Bwayo, J., Phase 2A Dose and Route Study of a DNA Prime MVA Boost Vaccine Candidate, in AIDS Vaccine 2005 International Conference, Montreal, Quebec, Canada, 2005.
E. Vardas, Pantaleo, G., Bart, P. A., Robinson, A., Pieterse, C., Thomas, R., McIntyre, J., Gray, G., Bogoshi, M., Mayaphi, S., Fast, P., Schmidt, C., Gilmour, J., Tarragona, T., Smith, C., and Dally, L., Safety and Immunogenicity of MVA.HIVA by 3 Different Routes, in AIDS Vaccine 2005 International Conference, Montreal, Quebec, Canada, 2005.
W. Jaoko, Kayitenkore, K., G Manyonyi, O., Karita, E., Schmidt, C., Fast, P., Komaroff, W., Cooper, A., Boaz, M., Gilmour, J., Dally, L., Ho, M., Smith, C., and Graham, B., Safety and Immunogenicity of VRC Multiclade HIV-1 Adenoviral Vector Vaccine Alone or with VRC Multiclade HIV-1 DNA Plasmid Vaccine in the African Adults, in AIDS Vaccine 2007 Conference, Seattle, WA, 2007.
Journal Article
N. Goonetilleke, Moore, S., Dally, L., Winstone, N., Cebere, I., Mahmoud, A., Pinheiro, S., Gillespie, G., Brown, D., Loach, V., Roberts, J., Guimar-Walker, A., Hayes, P., Loughran, K., Smith, C., DeBont, J., Verlinde, C., Vooijs, D., Schmidt, C., and McMichael, A. [..], Induction of Multifunctional Human Immunodeficiency Virus Type 1 (HIV-1)-Specific T Cells Capable of Proliferation in Healthy Subjects by Using a Prime-Boost Regimen of DNA-and Modified Vaccinia Virus Ankara-Vectored Vaccines Expressing [..] Epitopes, J Virol, vol. 80, pp. 4717-4728, 2006.
A. Guimarães-Walker, Mackie, N., McCormack, S., Hanke, T., Schmidt, C., Gilmour, J., Barin, B., McMichael, A., Weber, J., Legg, K., Babiker, A., Hayes, P., Gotch, F., Smith, C., Dally, L., Dorrell, L., Cebere, I., Kay, R., Winstone, N., Moore, S., Goonetilleke, N., and Fast, P., Lessons from IAVI-006, a phase I clinical trial to evaluate the safety and immunogenicity of the pTHr.HIVA DNA and MVA.HIVA vaccines in a prime-boost strategy to induce HIV-1 specific T-cell responses in healthy volunteers., Vaccine, vol. 26, no. 51, pp. 6671-7, 2008.
S. Vasan, Schlesinger, S., Chen, Z., Hurley, A., Lombardo, A., Than, S., Adesanya, P., Bunce, C., Boaz, M., Boyle, R., Sayeed, E., Clark, L., Dugin, D., Boente-Carrera, M., Schmidt, C., Fang, Q., Ba, L., Huang, Y., Zaharatos, G., Gardiner, D., Caskey, M., Seamons, L., and Ho, M., Phase 1 Safety and Immunogenicity Evaluation of ADMVA, a Multigenic, Modified Vaccinia Ankara-HIV-1 Clade B'/C Candidate Vaccine, PLOS One, vol. 5, p. e8816, 2010.
S. Vasan, Schlesinger, S., Huang, Y., Hurley, A., Lombardo, A., Chen, Z., Than, S., Adesanya, P., Bunce, C., Boaz, M., Boyle, R., Sayeed, E., Clark, L., Dugin, D., Schmidt, C., Song, Y., Seamons, L., Dally, L., Ho, M., Smith, C., Markowitz, M., Cox, J., Gill, D., and Gilmour, J., Phase 1 Safety and Immunogenicity Evaluation of ADVAX a Multigenic, DNA-Based Clade C/B’ HIV-1 Candidate Vaccine, PLoS ONE, vol. 5, p. e8617, 2010.
S. Mehendale, van Lunzen, J., Clumeck, N., Rockstroh, J., Vets, E., Johnson, P. R., Anklesaria, P., Barin, B., Boaz, M., Kochhar, S., Lehrman, J., Schmidt, C., Peeters, M., Schwarze-Zander, C., Kabamba, K., Glaunsinger, T., Sahay, S., Thakar, M., ,, and Heald, A., A Phase 1 Study to Evaluate the Safety and Immunogenicity of a Recombinant HIV Type 1 Subtype C Adeno-Associated Virus Vaccine, AIDS Research and Human Retroviruses, vol. 24, pp. 873-880, 2008.
E. Vardas, Kaleebu, P., Bekker, L., Hoosen, A., Chomba, E., Johnson, P., Anklesaria, P., Birungi, J., Barin, B., Boaz, M., Cox, J., Lehrman, J., Stevens, G., Gilmour, J., Tarragona, T., Hayes, P., Lowenben, S., Kizito, E., Fast, P., Heald, A., and Schmidt, C., A Phase 2 Study to Evaluate the Safety and Immunogenicity of a Recombinant HIV Type 1 Vaccine Based on Adeno-Associated Virus, AIDS Res Hum Retroviruses, vol. 26, pp. 933-942, 2010.
I. Cebere, Dorrell, L., McShane, H., Simmons, A., McCormack, S., Schmidt, C., Smith, C., Brooks, M., Roberts, J. E., Darwin, S. C., Fast, P. E., Conlon, C., Rowland-Jones, S., McMichael, A. J., and Hanke, T., Phase I Clinical Trial Safety of DNA- and Modified Virus Ankara-Vectored Human Immunodeficiency Virus Type 1 (HIV-1) Vaccines Administered Alone and in a Prime-Boost Regime to healthy HIV-1 Uninfected Volunteers, Vaccine, vol. 24, pp. 417-425, 2006.
F. Nakwagala, Birungi, J., Schmidt, C., Nanvubya, A., Konde, C., Hughes, P., Mugisha, E., Johnson, B., Muluubya, A., Nielsen, L., Gilmour, J., Gibiansky, L., Smith, C., Fast, P., and Kaleebu, P., Safety and immunogenicity of HIV-1 clade A vaccines in healthy, HIV uninfected adult Ugandan volunteers, 2004.
B. S. Peters, Jaoko, W., Vardas, E., Panayotakopoulos, G., Fast, P., Schmidt, C., Gilmour, J., Bogoshi, M., G Manyonyi, O., Dally, L., Klavinskis, L., Farah, B., Tarragona, T., Bart, P. - A., Robinson, A., Pieterse, C., Stevens, W., Thomas, R., Barin, B., and Bwayo, J. [..], Studies of a Prophylactic HIV-1 Vaccine Candidate Based on Modified Vaccinia Virus Ankara (MVA) with and without DNA Priming: Effects of Dosage and Route on Safety and Immunogenicity, Vaccine, vol. 25, pp. 2120-2127, 2007.